Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of two distinct medications: citalopram, a selective serotonin reuptake inhibitor (SSRI) antidepressant used primarily for depression, and zolpidem, a non-benzodiazepine hypnotic medication used for the short-term treatment of insomnia. When used concomitantly, these medications have a moderate drug interaction that requires clinical monitoring due to potential additive sedative effects. ## Drug Interaction Profile When used together, citalopram and zolpidem have a moderate drug interaction that requires clinical attention. The primary concerns with this combination include: **Increased Sedation Risk**: Both medications can cause drowsiness, and when combined, they may lead to excessive sedation, dizziness, and impaired coordination. This combination can affect a person's ability to focus and control movements, potentially increasing the risk of falls and accidents. **CNS Depression**: The additive central nervous system depressant effects can be problematic, especially in older adults who may be more sensitive to these effects. **Metabolism Considerations**: Zolpidem is metabolized via the CYP3A4 enzyme system, while citalopram may affect various cytochrome P450 pathways, potentially altering drug metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on citalopram + zolpidem.